Literature DB >> 27671684

Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

Daniel L Faden1, Alain Algazi2.   

Abstract

Entities:  

Year:  2016        PMID： 27671684     DOI： 10.1093/jnci/djw190

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  13 in total

Review 1.  [Odontogenic tumours and bone tumours of the jaw : Changes in the new WHO classification].

Authors:  D Baumhoer
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

Review 2.  [Cystic lesions of the jaws].

Authors:  D Baumhoer; S Höller
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

3.  [BRAF gene mutations in ameloblastic fibromas].

Authors:  Z You; L L Xu; X F Li; J Y Zhang; J DU; L S Sun
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-02-18

4.  BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.

Authors:  Adepitan A Owosho; Adeola M Ladeji; Kehinde E Adebiyi; Mofoluwaso A Olajide; Ikechukwu S I Okoye; Temitope Kehinde; Ngozi N Nwizu; Kurt F Summersgill
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-11-24       Impact factor: 2.503

5.  Image segmentation-based volume approximation-volume as a factor in the clinical management of osteolytic jaw lesions.

Authors:  Martin Kauke; Ali-Farid Safi; Andrea Grandoch; Hans-Joachim Nickenig; Joachim Zöller; Matthias Kreppel
Journal:  Dentomaxillofac Radiol       Date:  2018-09-21       Impact factor: 2.419

6.  Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.

Authors:  Gustavo S Fernandes; Daniel M Girardi; João Paulo G Bernardes; Felipe P Fonseca; Eduardo R Fregnani
Journal:  BMC Cancer       Date:  2018-09-12       Impact factor: 4.430

7.  BRAF inhibitor: a novel therapy for ameloblastoma in mandible.

Authors:  Masanobu Abe; Liang Zong; Takahiro Abe; Hideyuki Takeshima; Jiafu Ji; Toshikazu Ushijima; Kazuto Hoshi
Journal:  Chin J Cancer Res       Date:  2018-12       Impact factor: 5.087

8.  Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma.

Authors:  Maxime Brunet; Emmanuel Khalifa; Antoine Italiano
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

9.  Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma.

Authors:  Chih-Huang Tseng; Pei-Hsuan Lu; Yi-Ping Wang; Julia Yu Fong Chang
Journal:  J Pers Med       Date:  2022-01-08

Review 10.  The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors.

Authors:  Letícia Martins Guimarães; Bruna Pizziolo Coura; Ricardo Santiago Gomez; Carolina Cavalieri Gomes
Journal:  Front Oral Health       Date:  2021-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.